Editorial focus: understanding off-target effects as the key to successful RNAi therapy

With the first RNA interference (RNAi) drug (ONPATTRO (patisiran)) on the market, we witness the RNAi therapy field reaching a critical turning point, when further improvements in drug candidate design and delivery pipelines should enable fast delivery of novel life changing treatments to patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Bartoszewski, Rafal, Sikorski, Aleksander F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902517/
https://www.ncbi.nlm.nih.gov/pubmed/31867046
http://dx.doi.org/10.1186/s11658-019-0196-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902517/
https://www.ncbi.nlm.nih.gov/pubmed/31867046
http://dx.doi.org/10.1186/s11658-019-0196-3

Ejemplares similares